SPAS(SH:603168)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥157,239,879.38, representing a year-on-year increase of 17.06%[4] - The net profit attributable to shareholders for Q3 2023 was ¥6,097,934.85, a decrease of 36.65% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was -¥4,374,219.96, a decline of 148.41% year-on-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥498,793,167.68, an increase of 20.3% compared to ¥414,414,612.05 in the same period of 2022[20] - Total operating costs for the first three quarters of 2023 were ¥443,241,120.29, up 19.6% from ¥370,412,816.47 in the previous year[20] - Net profit for the third quarter of 2023 was ¥79,196,484.37, a significant increase of 74.8% compared to ¥45,258,416.26 in the same quarter of 2022[22] - Basic earnings per share for the third quarter of 2023 were ¥0.21, compared to ¥0.14 in the same quarter of 2022, indicating a growth of 50%[22] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥2,080,087,592.26, reflecting a growth of 6.25% compared to the end of the previous year[5] - The total assets of the company as of the end of the third quarter of 2023 were ¥2,080,087,592.26, compared to ¥1,957,678,280.27 at the end of the third quarter of 2022, reflecting a growth of 6.2%[18] - The total liabilities increased to ¥296,341,391.58 in the third quarter of 2023, compared to ¥240,993,686.20 in the same period of 2022, representing a rise of 23.1%[18] - Total current liabilities amounted to CNY 205,816,952.14, with accounts payable at CNY 80,853,934.40 and contract liabilities at CNY 49,509,366.81[29] - Non-current liabilities totaled CNY 35,176,734.06, including lease liabilities of CNY 33,755,440.97 and deferred tax liabilities of CNY 1,421,293.09[29] - Total liabilities reached CNY 240,993,686.20, while total equity was CNY 1,716,684,594.07, resulting in a total liabilities and equity of CNY 1,957,678,280.27[30] Cash Flow - The cash flow from operating activities for the year-to-date period was -¥5,244,613.45, a decrease of 113.02% compared to the previous year[5] - Operating cash flow for the first three quarters of 2023 was RMB 420,467,694.23, compared to RMB 380,482,481.30 in the same period of 2022, representing an increase of approximately 10.4%[24] - Net cash flow from operating activities was negative RMB 5,244,613.45, a significant decline from a positive RMB 40,295,786.37 in the first three quarters of 2022[24] - Total cash inflow from investment activities was RMB 96,451,128.78, down from RMB 234,209,609.67 in the previous year, indicating a decrease of about 58.8%[25] - Cash outflow from investment activities increased to RMB 342,670,172.75 from RMB 232,189,099.17, marking a rise of approximately 47.6%[25] - The total cash and cash equivalents at the end of the period was RMB 420,324,791.98, a decrease from RMB 525,059,148.89 at the beginning of the year[25] Research and Development - The company reported a significant increase in R&D expenses, contributing to the decline in net profit for Q3 2023[9] - Research and development expenses for the third quarter of 2023 amounted to ¥50,847,826.59, up 29.6% from ¥39,158,482.89 in the same period last year[21] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[9] - Research and development efforts are being prioritized to innovate and improve existing product lines[31] Market and Strategic Outlook - Sales growth in eye drops and cephalosporin products positively impacted the net profit for the year-to-date period, which increased by 75.54%[9] - The company reported a significant increase in user data, with a focus on expanding its market presence and enhancing product offerings[31] - Future outlook includes plans for new product development and potential market expansion strategies to drive growth[31] - The company is exploring strategic acquisitions to enhance its competitive edge in the pharmaceutical industry[31] Changes in Financial Reporting - The company executed the new accounting standards starting January 1, 2023, which may impact financial reporting and analysis going forward[26] - The company’s total liabilities and equity structure will be affected by the adjustments made under the new accounting standards, particularly in deferred tax assets[27]